Only buyers: Shares of this pharmaceutical company are locked at 20 per cent upper circuit. Do you own it?
This stock is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.
One of the Top Gainers on the BSE today, shares of Mercury Laboratories Ltd surged and reached a new 52-week high of Rs 838.05 per share on BSE, after being locked in the 20 per cent upper circuit.
Mercury Laboratories Ltd is one of India's leading global pharmaceutical companies, for more than six decades. The company is engaged in forefront of formulating, developing, marketing, and distributing safe, innovative, and cost-effective pharmaceuticals that help to improve the quality of life of patients. Also, the manufacturing facility is adaptable in terms of dosage forms and batch size.
The company’s quarterly consolidated financial results reveal that the net sales for Q2FY23 increased 63.85 per cent compared to the same quarter last year. Operating profit for Q2FY23 increased to 105.3 per cent when compared to Q2FY22. The net profit soared to Rs 3.14 crore or 227 per cent in Q2FY23, contrasted to Rs 0.96 crore in Q2FY22.
Mercury Laboratories Ltd.’s volume has climbed by 6.05 times as of today, November 15, 2022. Despite a challenging inflationary environment, the company posted the highest gross margins this quarter; as a result, it has improved its capacity to continue its upward trend in terms of corporate expansion. The stock price had been trading flat in the previous sessions but today the company reached its all-time high upper circuit of Rs 838.05. Mercury Laboratories Ltd is currently available at a PE multiple of 21.47 and an ROE of 9.68, all of which indicate good management effectiveness.
Investors must keep an eye on this stock.